Nicholas Turner

Nicholas Turner has led pivotal clinical studies demonstrating that serial ctDNA monitoring can guide real-time treatment decisions in metastatic breast cancer, showing that detection of ESR1 and PIK3CA mutations in ctDNA during endocrine therapy predicts resistance and can trigger early treatment switching to more effective agents. His research at the Institute of Cancer Research has established ctDNA as a practical tool for monitoring endocrine therapy response and detecting acquired resistance mutations before clinical progression. His work is driving the implementation of ctDNA-guided adaptive therapy in routine breast cancer management.